Point-of-care CAR T cell manufacturing in Canada: CLIC-01 CD19 clinical trial [WEBINAR]

For more information, visit: https://www.miltenyibiotec.com/DE-en/... Developing a country-wide program to make lifesaving CAR T cell therapy accessible to patients is no small feat. In Canada, Dr. Natasha Kekre has been instrumental in driving the Canadian-Led Immunotherapies in Cancer (CLIC) research program to make this a reality.

In this webinar, Dr. Kekre of The Ottawa Hospital will present the multitude of unique challenges involved and how the program overcame them to offer CAR T cell therapy to patients across Canada who may otherwise be out of options.

Established in 2016, the CLIC program brings researchers, clinicians, and patients from across Canada together to build expertise and capacity for innovation in the promising field of cellular immunotherapy for cancer. The first CLIC clinical trial was launched in 2019 at The Ottawa Hospital and BC Cancer, with support from BioCanRx, BC Cancer, The Ottawa Hospital Foundation, and the Ontario Institute for Cancer Research.

Miltenyi Biotec is a global provider of products and services that empower biomedical discovery and advance cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Our technologies enable solutions for cellular research, cell therapy, cell manufacturing, and imaging. Our 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. In our commitment to the scientific community, we also offer comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 3,000 employees in 28 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.